
July 11 (Reuters) - Capricor Therapeutics Inc CAPR.O:
CAPRICOR THERAPEUTICS PROVIDES REGULATORY UPDATE ON DERAMIOCEL BLA FOR DUCHENNE MUSCULAR DYSTROPHY
CAPRICOR THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER TO CAPRICOR
CAPRICOR THERAPEUTICS INC - TO RESUBMIT BLA WITH PHASE 3 DATA IN Q3 2025
CAPRICOR THERAPEUTICS INC - FDA ADVISES CAPRICOR TO REQUEST MEETING FOR APPROVAL
CAPRICOR THERAPEUTICS: FDA SAID DERAMIOCEL BLA DOES NOT MEET STATUTORY REQUIREMENT FOR SUBSTANTIAL EVIDENCE OF EFFECTIVENESS